<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Pharmacological andNon-pharmacological Treatment of Adults with ADHD by </title>
      <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0</link>
      <description>What is the main points of this article?
How would this piece of research be used to effect practice (EBP)?
Is this research trustworthy? Explain and discuss.</description>
      <language>en-us</language>
      <pubDate>2018-09-17 09:48:53 UTC</pubDate>
      <lastBuildDate>2018-09-17 11:20:41 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Main points</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282197111</link>
         <description><![CDATA[<div>ADHD = Attention-deficient/hyperactivity disorder. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 09:56:08 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282197111</guid>
      </item>
      <item>
         <title>Main points</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282211870</link>
         <description><![CDATA[<div>When diagnosing a person with ADHD there must be at least one adult informant to indicate how that individual functions on a daily basis. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 10:35:25 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282211870</guid>
      </item>
      <item>
         <title>Main points</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282214674</link>
         <description><![CDATA[<div>The aim of this paper is to perform a review of the literature focusing on recent systematic reviews and meta-analyses relevant to the pharmacological and nom pharmacological treatment of adult ADHD, in order to assist clinicians in daily decision-making. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 10:43:38 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282214674</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282216782</link>
         <description><![CDATA[<div>Psychostimulants are the most commonly researched medications for ADHD in children, adolescents and adults.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 10:49:26 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282216782</guid>
      </item>
      <item>
         <title>Main point</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282217505</link>
         <description><![CDATA[<div>Atomoxetine is a non-psychostimulant pharmacological treatment. It has been found to be the superior to placebo. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 10:51:37 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282217505</guid>
      </item>
      <item>
         <title></title>
         <author>divaklein93</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282221435</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet.com/padlets/irjekg003bao" />
         <pubDate>2018-09-17 11:02:33 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282221435</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282222004</link>
         <description><![CDATA[<div>· Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric conditions,1 with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases</div><div> </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:04:15 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282222004</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282222333</link>
         <description><![CDATA[<div>All pharmalogical solutions studied prove more effective that placebo effect. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:05:14 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282222333</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223076</link>
         <description><![CDATA[<div>· In a meta-analysis on 2665 adults with ADHD, the use of psychostimulants was significantly correlated with a mean increase in resting heart rate of 5.7 bpm and an increased systolic blood pressure of mean 2 mm Hg.3</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:07:29 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223076</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223236</link>
         <description><![CDATA[<div>·Although, initially ADHD was considered as only a disorder of childhood, in the last few years it has been possible to definitely validate ADHD in adulthood.4</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:07:54 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223236</guid>
      </item>
      <item>
         <title>Is this trustworthy?</title>
         <author>hannah_tomlinson1</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223314</link>
         <description><![CDATA[<div>We believe this review is trustworthy as it has clearly referenced reliable sources. However, this information was recorded in 2017 and some unreliable websites were evident.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:08:07 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223314</guid>
      </item>
      <item>
         <title>Main Points</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223377</link>
         <description><![CDATA[<div>·Pharmacological treatment may be considered as the first choice and methylphenidate the first-line option (for the number of studies and participants collected).</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:08:17 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223377</guid>
      </item>
      <item>
         <title>How is this used in effective practice? </title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223665</link>
         <description><![CDATA[<div> </div><div>· Different countries can have licensed different medications and regulations may change between children/adolescents and adults. Extended-release clonidine and extended-release guanfacine have been approved by the FDA for the treatment of ADHD, but not specifically for adults. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:09:05 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223665</guid>
      </item>
      <item>
         <title>How is this used in effective practice? </title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223826</link>
         <description><![CDATA[<div>·North American practice parameters9 suggesting medication as first choice, and the European guidelines recommending a pharmacological</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:09:34 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223826</guid>
      </item>
      <item>
         <title>How is this used in effective practice? </title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223987</link>
         <description><![CDATA[<div> </div><div>· A systematic review by Castells et al15 suggests that methylphenidate is significantly more efficacious than placebo in reducing ADHD symptoms with a moderately large effect size (SMD 0.49, 95% CI 0.34 to 0.64) in the short term. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:09:59 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282223987</guid>
      </item>
      <item>
         <title>How is this used in effective practice?</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224190</link>
         <description><![CDATA[<div> </div><div>·Non-pharmacological treatments can be used as add-on to pharmacological treatment, but while we have evidence of efficacy in children and adolescents, we do not have any evidence of efficacy of multimodal treatments in adults. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:10:38 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224190</guid>
      </item>
      <item>
         <title>Is this trustworthy</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224304</link>
         <description><![CDATA[<div> </div><div>·In terms of non-pharmacological interventions, a series of recent meta-analyses from the European ADHD Guidelines Group (EAGG)8 failed to find solid empirical support for their efficacy for ADHD core symptoms. However, the EAGG concluded that non-pharmacological treatments might still be valuable for the treatment of comorbid conditions such as oppositional-defiant and emotional problems. </div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:10:57 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224304</guid>
      </item>
      <item>
         <title>Is this trustworthy</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224402</link>
         <description><![CDATA[<div>·We identified a total of 40 papers. Psychostimulants—such as methylphenidate, dexamphetamine, mixed amphetamine salts and lisdexamfetamine—and non-psychostimulants—such as atomoxetine—were the most studied agents.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:11:15 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224402</guid>
      </item>
      <item>
         <title>Is this trustworthy</title>
         <author>cameron_mcadam</author>
         <link>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224540</link>
         <description><![CDATA[<div>·A systematic review by Castells et al15 suggests that methylphenidate is significantly more efficacious than placebo in reducing ADHD symptoms with a <strong>moderately large effect size (SMD 0.49, 95% CI 0.34 to 0.64)</strong> in the short term.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-09-17 11:11:36 UTC</pubDate>
         <guid>https://padlet.com/hannah_tomlinson1/geka95qhc5c0/wish/282224540</guid>
      </item>
   </channel>
</rss>
